October 23, 2026

FDA clears at-home risankizumab induction

Week 12 remission reached 56% vs. 30% with placebo, with the FDA revising tuberculosis testing precautions.

MDSpire News

October 23, 2026

Lupus nephritis may remit despite HIV

A patient with biopsy-confirmed renal disease achieved remission during immunosuppressive therapy while maintaining stable HIV control.

MDSpire News

October 22, 2026

FDA approves ravulizumab for IgA nephropathy

Phase 3 results showed reduced proteinuria at 34 weeks, but effects on kidney function remain unconfirmed.

MDSpire News

October 22, 2026

STAT6 may aid diagnosis of giant pulmonary SFT

Immunohistochemical testing confirmed a rare tumor despite low-grade histology, extensive local involvement, and suspected liver metastasis.

MDSpire News

October 21, 2026

FDA approves liquid cevimeline for Sjögren disease

The new oral solution offers an alternative to capsules for adults with dry mouth, including those with swallowing difficulties.

MDSpire News

October 16, 2026

FDA approves first at-home therapy for thyroid eye disease

The first at-home subcutaneous treatment for thyroid eye disease met its primary end point in 1 of 2 phase 3 trials.

MDSpire News

October 14, 2026

FDA expands bladder cancer therapy approval

The expansion offers another treatment option for patients with high-grade tumors following BCG failure.

MDSpire News

October 12, 2026

CDC: Measles cases surpass 4,000 in 2026

CDC data show that 96% of cases are outbreak-associated, with adults accounting for 40% of cases, up from 29% in 2025.

MDSpire News

October 09, 2026

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

MDSpire News

October 05, 2026

Rare GI disease leads to 20-plus units of transfused blood

A rare intestinal lymphangioma caused life-threatening bleeding without typical laboratory features of protein-losing enteropathy

MDSpire News